EP 1677803 A2 20060712 - METHOD OF INHIBITING THE EXPRESSION OF A MULTI-DRUG RESISTANCE GENES AND INHIBITING THE PRODUCTION OF PROTEINS RESULTING FROM THE EXPRESSION OF SUCH GENES THEREBY ENHANCING THE EFFECTIVENESS OF CHEMOTHERAPEUTIC AGENTS TO TREAT CANCERS
Title (en)
METHOD OF INHIBITING THE EXPRESSION OF A MULTI-DRUG RESISTANCE GENES AND INHIBITING THE PRODUCTION OF PROTEINS RESULTING FROM THE EXPRESSION OF SUCH GENES THEREBY ENHANCING THE EFFECTIVENESS OF CHEMOTHERAPEUTIC AGENTS TO TREAT CANCERS
Title (de)
VERFAHREN ZUR HEMMUNG DER EXPRESSION VON GENEN MIT MULTI-ARZNEIMITTEL-RESISTENZ UND HEMMUNG DER PRODUKTION VON PROTEINEN, DIE SICH AUS DER EXPRESSION DIESER GENE ERGEBEN, UND SO VERSTÄRKUNG DER WIRKSAMKEIT VON CHEMOTHERAPEUTIKA ZUR BEHANDLUNG VON KREBS
Title (fr)
METHODE DESTINEE A INHIBER L'EXPRESSION DE GENES DE MULTIRESISTANCE AUX MEDICAMENTS ET A INHIBER LA PRODUCTION DE PROTEINES RESULTANT DE L'EXPRESSION DE CES GENES EN VUE D'AMELIORER L'EFFICACITE D'AGENTS CHIMIOTHERAPEUTIQUES POUR LE TRAITEMENT DES CANCERS
Publication
Application
Priority
- CA 2004001697 W 20040927
- US 67305103 A 20030926
Abstract (en)
[origin: WO2005030225A2] ABSTRACT OF THE INVENTION The present invention provides, in one aspect, a method of inhibiting the expression of a multi-drug resistance gene in an animal cell which comprises administering to an animal an effective amount of at least one cholesterol absorption inhibitor. In another aspect, it provides a method of inhibiting the production of a protein expressed by a multi-drug resistance gene in an animal cell which comprises administering to an animal an effective amount of at least one cholesterol absorption inhibitor. In another aspect, the present invention provides a method of enhancing the effectiveness of a chemotherapeutic agent in an animal having cancer, which comprises administering to said animal an effective amount of the chemotherapeutic agent and at least one cholesterol absorption inhibitor. Further, there are provided compositions and kits for use in cancer treatment which comprise at least one chemotherapeutic agent and at least one cholesterol absorption inhibitor.
IPC 1-7
A61K 31/683; A61P 35/00; A61K 31/568; A61K 31/397; A61K 31/665; A61K 31/661
IPC 8 full level
A61K 31/397 (2006.01); A61K 31/568 (2006.01); A61K 31/661 (2006.01); A61K 31/665 (2006.01); A61K 31/683 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC (source: EP KR)
A61K 31/397 (2013.01 - EP); A61K 31/56 (2013.01 - KR); A61K 31/568 (2013.01 - EP); A61K 31/575 (2013.01 - KR); A61K 31/661 (2013.01 - EP); A61K 31/665 (2013.01 - EP); A61K 31/683 (2013.01 - EP); A61K 45/06 (2013.01 - EP); A61P 1/00 (2017.12 - EP); A61P 1/14 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 43/00 (2017.12 - EP)
Citation (search report)
See references of WO 2005030225A2
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
DOCDB simple family (publication)
WO 2005030225 A2 20050407; WO 2005030225 A3 20050526; AU 2004275444 A1 20050407; BR PI0414812 A 20061114; CA 2540364 A1 20050407; CN 1874780 A 20061206; EP 1677803 A2 20060712; JP 2007524651 A 20070830; KR 20060135615 A 20061229; RU 2006114049 A 20071120
DOCDB simple family (application)
CA 2004001697 W 20040927; AU 2004275444 A 20040927; BR PI0414812 A 20040927; CA 2540364 A 20040927; CN 200480031697 A 20040927; EP 04761853 A 20040927; JP 2006527239 A 20040927; KR 20067005929 A 20060324; RU 2006114049 A 20040927